| 1 | 09:10-09:30 |
How to Be a Good Surgeon |
|
|||||||||||||||||
| 2 | 09:30-09:50 |
Surgery in the Age of AI: Where Are We Headed? |
|
|||||||||||||||||
| 3 | 09:50-10:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 10:05-10:20 |
Artificial Intelligence - Blessing or Curse for The Urologists? |
|
|||||||||||||||||
| 2 | 10:20-10:35 |
Urological training in the Digital Era: Challenges and Benefits |
|
|||||||||||||||||
| 3 | 10:35-10:50 |
Optimizing urinary outcomes after radical prostatectomy |
|
|||||||||||||||||
| 4 | 10:50-11:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 11:05-11:20 |
cTURBT Combined With PLND and Targeted Therapy Plus Immunotherapy as a Comprehensive Radiotherapy-Free Bladder-Sparing Strategy: A Prospective, Multicenter, Single-Arm Clinical Trial in HER2-Overexpressing MIBC |
|
|||||||||||||||||
| 2 | 11:20-11:35 |
redefining the Perioperative treatment landscape for MIBC |
|
|||||||||||||||||
| 3 | 11:35-11:50 |
Reflections on Optimizing Treatment Regimens for Chinese Patients with mHSPC |
|
|||||||||||||||||
| 4 | 11:50-12:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 12:05-12:15 |
Minimal invasive treatment of renal cell carcinoma with IVC thrombus |
|
|||||||||||||||||
| 2 | 12:15-12:25 |
CUA Urinary Tract Reconstruction Committee: Buccal Mucosal Graft Multicenter Study and Platform Development |
|
|||||||||||||||||
| 3 | 12:25-12:35 |
Reinvestigation of Microsurgical Varicocelectomy Based on Anatomical Findings |
|
|||||||||||||||||
| 4 | 12:35-12:45 |
The innovation treatment of Pediatric Bladder Outlet Obstruction: 301 Experience |
|
|||||||||||||||||
| 5 | 12:45-13:00 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 13:00-13:10 |
Target-Driven, Evidence-Based Breakthroughs: AKT Inhibitors Open a New Chapter in Targeted Therapy for Prostate Cancer |
|
|||||||||||||||||
| 2 | 13:10-13:20 |
Robot-Assisted Radical Prostatectomy Without Prior Biopsy in Patients Selected by Concordant mpMRI and PSMA PET/CT Positivity: Interim Analysis of a Prospective Multicenter Randomized Controlled Trial |
|
|||||||||||||||||
| 3 | 13:20-13:30 |
Differential Treatment Response of Bladder Cancer: From Clinical Trial Findings to CBCC Real-World Exploration |
|
|||||||||||||||||
| 4 | 13:30-13:40 |
Efficacy and Safety of Cyclosporine A for Bladder Pain Syndrome/Interstitial Cystitis with Hunner Lesions |
|
|||||||||||||||||
| 5 | 13:40-13:55 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 13:55-14:05 |
AI in Urolithiasis: What Can It Do? |
|
|||||||||||||||||
| 2 | 14:05-14:15 |
The application of artificial intelligence in urodynamic diagnosis evaluation and closed-loop neuromodulation therapy. |
|
|||||||||||||||||
| 3 | 14:15-14:25 |
Multimodal Image Fusion-Guided Precise Navigation for Laser Ablation Therapy of Prostate Cancer |
|
|||||||||||||||||
| 4 | 14:25-14:35 |
A Pathology Foundation Model Driving Full-Process Management of Prostate Cancer |
|
|||||||||||||||||
| 5 | 14:35-14:50 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 14:50-15:00 |
Screening and Treatment for Hypogonadism: The Advantages of Using Gels |
|
|||||||||||||||||
| 2 | 15:00-15:10 |
CXCR4 receptor imaging-based surgical classification (CRISC) system: a novel subtyping system for guiding surgical management of primary aldosteronism. |
|
|||||||||||||||||
| 3 | 15:10-15:20 |
Analysis of a Multicenter Randomized Controlled Clinical Trial of Water Vapor Thermal Ablation System for Benign Prostatic Hyperplasia |
|
|||||||||||||||||
| 4 | 15:20-15:30 |
Efficacy and Safety of ¹⁷⁷Lu-PSMA-617 Combined with ADT and ARPI in PSMA+ mHSPC: A Subgroup Analysis of Chinese Population from the PSMAddition Trial |
|
|||||||||||||||||
| 5 | 15:30-15:45 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 15:45-15:55 |
Stable Disease Control for Long-term Survival: Redefining the Management Goals of mPC |
|
|||||||||||||||||
| 2 | 15:55-16:05 |
Phase Results and Iterative Updates of the Research Project on the Current Status and Awareness of Non-Complex Urinary Tract Infection Treatment in China |
|
|||||||||||||||||
| 3 | 16:05-16:15 |
Development of a Standardized Care and Tiered Referral Framework for Upper Tract Urothelial Carcinoma in Primary and Secondary Healthcare Settings in China |
|
|||||||||||||||||
| 4 | 16:15-16:25 |
Predictive Analysis of Urinary Incontinence Recovery Trajectories After Robot-Assisted Radical Prostatectomy: A Single-Center Real-World Study |
|
|||||||||||||||||
| 5 | 16:25-16:40 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 16:40-16:50 |
Preliminary Exploration of Kidney Xenotransplantation: The Chinese Experience |
|
|||||||||||||||||
| 2 | 16:50-17:00 |
MetaFlow Targeted Waterjet Resection System for the Treatment of Benign Prostatic Hyperplasia: A Prospective, Multicenter, Randomized Controlled Noninferiority Trial MetaFlow |
|
|||||||||||||||||
| 3 | 17:00-17:10 |
Novel CAR-T Therapy for Advanced Refractory Prostate Cancer |
|
|||||||||||||||||
| 4 | 17:10-17:25 |
Discussion and Comments |
|
|||||||||||||||||